News Hub | News Direct

Expert Tips to Support and Celebrate Aging Pets

YourUpdateTV

Many pet owners struggle with the reality of their furry friends aging. Dr. Stacey Bone, veterinarian and senior pet advocate with Hill’s Pet Nutrition recently talked about the importance of embracing, not fearing, this natural process and how proper nutrition and care can help pets live bold in their older years. A video accompanying this announcement is available at: https://youtu.be/nhs96_Yu3Uc According to a 2019 study by The American Animal Hospital Association, 80% of pet owners do not realize the age at which their pet is considered a senior pet – which is typically age 7. Just like humans, pets’ biology changes as they age, but getting older doesn't have to make life any less exciting. Pet parents fear aging, because “getting old” is associated with slowing down and losing the spirit and vibrancy that makes their pets special. The fear associated with owning a senior pet can potentially lead to inadequate care for senior pets, resulting in health issues and decreased quality of life. There are attainable ways to support your senior pet’s changing needs. Knowing how to best care for your pet – from tailored nutrition for senior pets to regular veterinary care - can help pet parents continue to experience a full life together.   Tailored Nutrition for Senior Pets Hill’s Pet Nutrition is raising awareness of the unique nutritional needs of senior pets and how important it is to switch to a food designed specifically for seniors, such as Hill’s Science Diet Senior Vitality. The right nutrition can help senior pets live life to the fullest, so it is important to transition your pet to a senior pet food that meets his or her needs. Hill’s Science Diet Senior Vitality is made for older pets’ changing biology, including balanced minerals for heart and kidney health, omega-6 fatty acids and vitamin E for healthy skin and coat, and easy-to-digest ingredients to support digestion. Hill’s Science Diet Senior Vitality improves senior pets’ everyday ability to get up and go. It features nutrition that can help support the brain function, interaction and overall energy and vitality of your senior pet. In a clinical study, pet parents observed increased affection and stamina in as little as 28 days when their pets ate Senior Vitality dry dog food. The best food for aging pets is one formulated to keep up with their changing nutritional requirements. Talk with your veterinarian to ensure your dog or cat is getting the right nutrition at each lifestage.   Encouraging Senior Pet Adoption There are many animals in shelters across the nation who need homes, and some of the most overlooked pets include seniors. Hill’s Pet Nutrition is encouraging people to consider opening their hearts and homes to a senior pet in a shelter. Senior pets tend to spend the longest time at shelters and are often viewed as unadoptable based on the misperception that they likely have behavioral issues. In reality, many of these animals were companions to elderly people who passed away or moved to an assisted living facility. Only 25% of senior pets get adopted, compared to a 60% adoption rate for younger pets, according to the ASPCA. Puppies and kittens are cute, but they also need a ton of extra attention and training. On the other hand, senior pets are overflowing with love and their laid-back personalities make them perfect for lots of different homes. Along with expert care from shelter staff, quality nutrition can play a vital role in helping shelter pets be healthy, happy and more adoptable. That’s why Hill’s Food, Shelter & Love program provides science-led nutrition to hundreds of shelters across North America, helping more than 14 million pets find new homes since 2002. For more information, visit hillspet.com and search ‘Senior Care’ to learn more about care and nutrition for senior pets. About Dr. Stacey Bone: Dr. Stacey Bone brings over 16 years of expertise to his role as a small animal veterinarian, where he currently serves both as a relief veterinarian and as a senior brand manager at Hill's Pet Nutrition. Within Hill's, he is part of the Prescription Diet marketing team, driving the company's strategic vision in the U.S. market. With a heartfelt commitment to geriatric pet care, Dr. Bone focuses on areas critical to the health of senior pets, including advanced nutrition, comprehensive disease management, and the importance of preventive care. That passion led him to found a company dedicated to creating products that address the unique issues of senior pets. His work is characterized by a deep understanding of veterinary science, coupled with genuine care for his animal patients. Dr. Bone is an advocate for educating pet parents about the impactful role that nutrition plays in senior pet health: “Most pet parents do not like to acknowledge that their pet is getting older, but celebrating aging, rather than fearing it, can help those animals live long, full lives. In partnership with your veterinarian, it is important to transition your pet to a senior pet food that meets his or her needs. Providing age-appropriate nutrition supports overall energy and mobility and can help pets live life to the fullest.” Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 18, 2024 04:30 PM Eastern Daylight Time

Video

Shedding Light on Cystic Fibrosis

YourUpdateTV

Cystic fibrosis (CF) is a rare, progressive, and genetic disease that currently affects about 40,000 people in the United States. CF is the result of a defective gene, inherited from each parent, and the disease can impact people of all races and ethnicities. Recently, KC White, Board Chair of the Cystic Fibrosis Foundation, participated in a nationwide satellite media tour to discuss the disease, her personal journey, and how the Foundation is helping progress care and treatment options. A video accompanying this announcement is available at: https://youtu.be/8wj8u0JEqLU CF is a life-shortening disease that prevents our bodies from clearing mucus. This can lead to lung infections, poor nutrition, lung disease, and a host of unique challenges that can impact every aspect of a person’s life. When it was first discovered, it was considered a fatal pediatric disease. But due to transformative advancements in treatments and high-quality care, the life-expectancy for someone born with CF today is 56. While that number is climbing there is still a long way to go and unfortunately, not all people with CF equally benefit from this progress. KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood and is the first person with CF to serve as board chair. When she was diagnosed, she wasn’t expected to live past high school age, but her family refused to accept that fate, which prompted their dedication to the Foundation’s work. Because of recent treatments known as modulators, about 90% of the CF population (including KC) experienced an incredible transformation in their health. With this though, comes navigating unplanned challenges including careers, finances, family, and more. In addition to fueling the research, particularly in genetic therapies, that will lead to transformative treatments for the entire CF population, the CF Foundation works to support the CF community in all aspects of their lives through support programs and fostering connection opportunities. The CF Foundation is committed to finding a cure and providing all people with CF the opportunity to lead long, fulfilling lives. The Foundation is aggressively funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. For more information, visit CFF.ORG About KC White KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood, speaking at her first Foundation event when she was only 9 years old. She is the first person with CF to serve as board chair. White received her Master of Applied Positive Psychology from the University of Pennsylvania in 2022 and currently serves as an assistant instructor in the program. She is also the Head Varsity Women’s Lacrosse coach for the Chagrin Falls, Ohio, Tigers. She and her husband, Justin, have one son, Mac. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is a donor-supported nonprofit organization leading the relentless pursuit of a cure for cystic fibrosis. The Foundation is committed to providing all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. The organization supports and accredits a national network of over 130 CF care centers recognized by the National Institutes of Health as a model of care for a chronic disease. Also, the Foundation manages support programs and fosters connection opportunities for the CF community. Based in Bethesda, Md., the Foundation’s impact is made possible by the work of nearly 70 local chapters across the country. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 17, 2024 01:46 PM Eastern Daylight Time

Video

Roberts & Ryan Inc. expands its internship program in partnership with the Boys and Girls Club of Harlem.

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned (SDVO) broker-dealer, announced the expansion of its summer internship program, which recently accepted 13 candidates from a diverse pool of students from a variety of schools and backgrounds. The expansion reflects the company’s commitment to supporting veterans and underprivileged youth. “At Roberts & Ryan, we believe that supporting future generations of financial professionals is important to the long-term success of our industry. This year’s internship class was bolstered by our relationship with the Boys & Girls Club of Harlem, who recommended two exceptional candidates, creating more opportunities for diverse talent in the financial services industry,” said Brian Rathjen, President of Roberts & Ryan. Seven interns completed Roberts & Ryan's internship program in 2023, a number the firm nearly doubled in 2024 due to increased student demand. Roberts & Ryan runs two internship cohorts per year to provide students from a variety of backgrounds with real-world experience in the financial services industry. Interns collaborate with experienced professionals on projects that demonstrate a range of services provided by Roberts & Ryan, from secondary equity and fixed income trading to debt and equity capital markets, business development, compliance, and marketing. Roberts & Ryan was recently approved for membership by the New York Stock Exchange, and summer interns have access to its iconic trading floor. "Breaking into the financial services industry can be a challenge, as most entry-level positions require either previous work experience or a professional connection with someone in the industry. We believe that our program provides our interns with both,” said Edward D’Alessandro, Chief Executive Officer of Roberts & Ryan. Roberts & Ryan is committed to increasing access to opportunities in the financial sector by finding high-quality candidates for their internship program. Through the program, interns gain valuable experience, make important connections, and build a talent stack for a successful career in finance. For current undergraduate and graduate students interested in participating in next year’s internship program, please email your resume to info@roberts-ryan.com. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

June 13, 2024 09:00 AM Eastern Daylight Time

Image

Stupid Cancer Announces CancerCon Live 2024 in Austin, Texas

Stupid Cancer

Stupid Cancer, the leading nonprofit organization dedicated to empowering everyone affected by adolescent and young adult (AYA) cancer, is thrilled to announce that CancerCon Live 2024 will take place in Austin, Texas for the first time ever. This landmark event, scheduled for August 15 - 18, 2024 at the Hyatt Regency Austin, promises to bring together hundreds of young adult cancer patients, survivors, caregivers, and advocates from across the country to share their experiences, gain valuable insights/resources, and build lasting connections. “We look forward to creating an unforgettable experience that empowers young adults affected by cancer and helps them connect with others who truly understand their journey.” says Alison Silberman, CEO of Stupid Cancer. CancerCon Live is the premier annual gathering for the AYA cancer community, offering a unique blend of education, support, and empowerment. This year's event in Austin will feature: Keynote Speakers: Hear from leading voices in the AYA cancer community, including survivors, healthcare professionals, and advocates, sharing their stories and insights on topics ranging from advancements in cancer treatment to survivorship challenges. Workshops and Panels: Participate in interactive sessions on a wide range of topics tailored to the unique needs of AYA cancer patients, survivors, and caregivers, covering mental health, fertility preservation, advocacy, career development, and more. Meet the AYA Community: Dedicated time for attendees to connect with peers, build lasting friendships, and expand their support networks in a supportive and inclusive environment. Exhibit Hall: Explore resources, products, and services from leading organizations committed to supporting the AYA cancer community as well as a few local small businesses. Social Events: Enjoy fun and engaging social activities designed to foster connections and create memorable experiences with some local Austin flavor. Local excursions: Attendees will have the opportunity to explore the city’s unique attractions, including Bat Watching under Congress Bridge and unlimited Skee-Ball at Full Circle Bar, to name a few, all while engaging in meaningful activities that support their personal and collective growth. “Austin’s dynamic and inclusive culture aligns perfectly with our mission to build a strong, supportive community for AYA cancer patients and survivors. We look forward to welcoming everyone to what promises to be our most impactful CancerCon yet,” says Eddie Mouradian, Director of Development. For over a decade, Stupid Cancer has brought together hundreds of patients, survivors, caregivers, advocates, and health professionals at the largest gathering of the AYA community - CancerCon (R). Now gathering both online and off, every CancerCon event is an immersive experience, led by transformative connection and education. The majority of conference attendees are AYA (age 15-39) cancer patients and survivors, but caregivers and health professionals of all ages are also welcome. CancerCon Live is hosted in a different US city each year as we seek to make the event always be within reach of our community at all times. Registration for CancerCon Live 2024 is now open. To register or learn more about the event, please visit cancercon.org. About Stupid Cancer Stupid Cancer’s mission is to help empower everyone affected by adolescent and young adult cancer by ending isolation and building community. Through innovative programming and strategic communications, the organization aims to provide support, resources, education, and a sense of community both online and in-person. For more information, please visit stupidcancer.org. For media inquires, contact: media@stupidcancer.org About Stupid Cancer:Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Contact Details Alison Silberman +1 646-868-0087 media@stupidcancer.org Company Website https://stupidcancer.org/

June 12, 2024 02:39 PM Eastern Daylight Time

Image

Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer

TBRIF

Therma Bright (TSXV:THRM) (OTCQB:TBRIF), a developer of a wide range of leading edge, proprietary diagnostic and medical device technologies that address some of today's most important medical and healthcare challenges, appears to be positioned for major growth based on one important upcoming catalyst. For some background, Therma Bright (TSXV:THRM) (OTCQB:TBRIF) sells Venowave, a compact, battery operated peristaltic pump that generates a wave-form motion. When worn below the knee and strapped to the calf, the resulting compression of the calf causes an increased upward volumetric displacement of venous and lymph fluid. The Venowave is FDA approved for 10 indications, including: Management of Post Thrombotic Syndrome, Prevention of Deep Vein Thrombosis (DVT / blood clots), treatment of Chronic Venous Insufficiency, as well as other conditions related to poor circulation in the extremities.It seems that the company is set to receive a newly issued, HCPCS Level II code to identify it’s Venowave device,which will be instrumental in driving revenue growth. HCPCS codes are a set of health care procedure codes used in the United States to standardize the reporting of medical procedures, services and devices. These codes are essential for billing and reimbursement purposes within the Medicare and Medicaid programs, and are also used by other healthcare insurers in the United States, including private insurance companies. Additionally, a preliminary Medicare Payment determination will be made for this new HCPCS code. If the Venowave is purchased outright, Medicare and Medicaid will reimburse $1,199 USD. If the unit is rented to the patient, Medicare and Medicaid will pay $78.05 USD / month for up to 13 months, for a total of $819.55 USD. These are very favourable numbers for Therma Bright when taking into account the manufacturing cost of Venowave. Additionally, private insurers such as blue cross blue shield, UnitedHealth Group, etc., also use these codes as guidelines to determine reimbursement payouts. Why is this so important? Previously, Venowave was placed into the E0676 HCPCS code. E0676 is a miscellaneous code with no set reimbursement, meaning that when Venowave is billed for under this code, Medicare and Medicaid, as well as private insurance companies will default to a $0 reimbursement. While it is possible to submit a package of medical necessity under this code, with a detailed explanation of the patients’ condition and why it should be reimbursed, the reality is that most physicians or prescribing parties will not go through this exercise as they are not reimbursed for the time and trouble it takes. Therma Bright experienced a similar situation with the temporary codes it was approved to sell Venowave under in 2023 – Without the prescribing party submitting a package of medical necessity, Venowave by default will not be paid for. Additionally, these reimbursement issues are a barrier to prescribing parties recommending Venowave, as they are not able to tell their patients if the device will be paid for. Physicians tend to shy away from prescribing devices in these categories, as they could leave their patient with a large unexpected medical bill, reflecting badly on the prescribing party. This new HCPCS code combined with the preliminary payment determination establishes a fixed payout for Venowave across public and private insurers in the United States, eliminating friction in payments as well as hesitancy by the prescribing parties in recommending the device. Therma Bright expects to receive this new HCPCS code and payment determination after the biannual CMS meeting which was held at the end of May, 2024. Venowave differentiates itself from other available compression products in a number of ways. Currently, pneumatic devices and simple products that squeeze the leg make up the majority of the compression market. Inexpensive portable compression devices simply squeeze and release the calf, and do not actively move fluid upwards towards the heart. Sequential compression devices are proven very effective, however they are not portable. Sequential compression devices have tubes attached to an air compressor which inflates chambers in sequence, providing sequential compression. Typically these devices can only be used while lying in bed, on a couch or in a similar position, and do not allow the patient to remain ambulatory. Venowave combines the best of both worlds, providing sequential compression without the use of tubes or wires, allowing the patient to remain completely ambulatory while receiving treatment. Additionally, Venowave is quiet, so patients can continue to receive treatment while they are sleeping or otherwise resting. Currently in the United States an estimated 25 million people are living with some form of Chronic Venous insufficiency. Most go untreated or rely on simple compression stockings for some form of minor relief, as proper treatment via sequential compression devices is too cumbersome and expensive. The issuance of this new HCPCS code and payment determination opens up these patients to the Venowave, a new and portable form of treatment that will not cost them anything out of pocket. This market alone, along with the management of Post Thrombotic Syndrome and prevention of primary thrombosis is potentially huge. Additionally, Therma Bright is working towards securing reimbursement for DVT prevention. While Medicare and Medicaid do not pay for DVT prevention, private insurers do. Therma Bright is confident that the issuance of this new HCPCS code and payment determination will help patients access Venowave for DVT prevention via their private health insurance, which is another huge addressable market in the United States. During the last year, Therma Bright has been meeting with potential distributors across the United States. Many have indicated interest in the Venowave pursuant to a positive outcome with regards to the HCPCS coding. Therma Bright currently has over 2000 Venowave units in inventory, which they expect can be moved right away upon the issuance of the HCPCS code. After these initial 2000 units are sent to distributors, placed on patients, and reimbursement received, Therma Bright conservatively estimates moving 500-1000 units / month. Given the high margin on Venowave, this will fare well for the company. As Venowave is a high margin product, the company is looking at the possibility of setting up a manufacturing operation in either the U.S, Canada or Mexico which would allow it to sell to the VA in the US. This would open up yet another large market for Venowave in the United States. For investors who may be interested in Therma Bright, it is important to note that Venowave isn’t its only product. The company also has respiratory health and consumer health product portfolios. The respiratory health product portfolio features the Digital Cough Test (DCT) app created by Therma Bright (TSXV:THRM) (OTCQB:TBRIF) and AI4LYF. The app uses artificial intelligence to detect multiple respiratory diseases by analyzing a person’s cough sound and has shown a high accuracy rate. The app is currently in the process of securing a 513g FDA clearance, which will allow the company to charge for Remote Therapeutic Monitoring (RTM) and be used for patient reimbursement. The consumer health product portfolio features devices designed for pain relief, cold sore prevention and insect bite relief. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and expects to be compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://RazorPitch.com

June 12, 2024 06:00 AM Eastern Daylight Time

Busting the Myths Around Weight Loss Medication

YourUpdateTV

Obesity is one of the most common chronic health issues in the U.S. today, and can lead to or exacerbate many other significant physical and mental health challenges, including type 2 diabetes, heart disease and depression. But GLP-1 injections are an impactful new tool that can help people on their weight loss journey. Recently, Dr. Craig Primack, the Senior Vice President of Weight Loss at Hims and Hers, participated in a nationwide satellite media tour to discuss the impact of obesity, common myths surrounding weight loss medications, and personalized options that can help. A video accompanying this announcement is available at: https://youtu.be/NGNz92bi7nY Research shows that even just 5-10% of body weight loss can improve blood pressure, blood sugar, cholesterol, joint pain, sleep apnea, and other weight-related conditions. Weight loss drugs like GLP-1 medication are not only an exciting tool in the weight loss tool belt but can help to address the challenges associated with obesity. GLP-1 injections can support healthy weight loss along with a reduced calorie diet and increased exercise. Some common myths regarding weight loss medications, include: ● Many people assume that weight loss medications are magic. Weight loss drugs can be excellent tools for decreasing hunger and therefore reducing overall calorie intake, but their effects are not instant and should be combined with a healthy lifestyle approach, including a balanced diet and regular exercise. ● People also assume that the injections are painful. The injection is a very small needle that goes just under the skin. It feels like a small pinch, and is quite painless. For the most part, people do great with self-administering GLP-1 injections. ● Lastly, many people think that weight loss drugs come with dangerous side effects. Like all medications, there is a risk of side effects, but there are really only three common side effects associated with GLP-1’s, and they are generally mild: nausea, heartburn, and constipation. The benefits of these drugs far outweigh the risks for many, especially when compared to the health risks associated with being overweight. Hims & Hers’ personalized approach means custom treatment for individual needs to minimize these side effects. Known for its holistic, personalized approach to health and wellness, Hims & Hers is now offering access to GLP-1 injections designed for affordability and effectiveness. These are the four things you should know. ● Hims & Hers’ weight loss program is tailored to an individual’s needs and includes customized medication kits or GLP-1 medication, as determined appropriate by the healthcare provider. ● The science-backed and doctor-developed program is available 100% online for as little as $199 a month. ● Through the app, a licensed healthcare provider will work with you to decide the recommended treatment, plus provide realistic nutritional tips with easy to follow snack and meal ideas. ● Hims & Hers takes the safety of each customer very seriously. The pharmacies the brand works with provide sterile, single-use syringes with each GLP-1 shipment, and products are made with active ingredients from FDA regulated suppliers. And, injection medications are shipped in cold packs for temperature control in transit in the summer weather. For more information, visit hims.com/glp1 or forhers.com/glp1 About Dr. Craig Primack MD, FACP, FAAP, MFOMA Dr. Craig Primack is the Senior Vice President of Weight Loss at Hims & Hers. He completed his undergraduate studies at the University of Illinois and subsequently attended medical school at Loyola University — The Stritch School of Medicine. He completed a combined residency in Internal Medicine and in Pediatrics at Banner University- Phoenix, and Phoenix Children's Hospital. He received post-residency training in Obesity Medicine and is one of about 7,000 physicians in the U.S. certified by the American Board of Obesity Medicine. In 2006, Dr. Primack co-founded Scottdale Weight Loss Center in Scottsdale, Arizona, where he began practicing full-time obesity medicine. Scottsdale Weight Loss Center has grown since then to six obesity medicine clinicians in four locations around the greater Phoenix Metropolitan area.From 2019–2021, he served as president of the Obesity Medicine Association (OMA), a society of over 5,400 clinicians dedicated to clinical obesity medicine. He proudly served on the OMA board from 2010-2024, most recently as ex-officio trustee. Dr. Primack routinely does media interviews regarding weight loss and regularly speaks around the country educating medical professionals about weight loss and obesity care. He is co-author of the book, “Chasing Diets.” Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 11, 2024 11:37 AM Eastern Daylight Time

Video

NOVUS INK Advisors and Solidus Capital Group Team-up to Serve Growing Transatlantic Commercial Interests of Mid-Market Enterprises

NOVUS INK Advisors

NOVUS INK Advisors and Solidus Capital Group signed a services agreement today to provide integrated senior advisory and execution services to small-and mid-market enterprises amid thriving commercial interests between the United States and Europe. The two firms aim to accelerate client services by combining expertise and resources to support growth into new markets, encompassing management counsel, valuation, performance tracking, board advisory, marketing, communication, public and government affairs. The collaboration will enable NOVUS INK Advisors and Solidus Capital Group to meet the unique needs of global small-and mid-market enterprise clients operating across business-to-consumer, business-to-business, and business-to-government segments. The transatlantic economy is proving remarkably robust in the face of global economic and geopolitical disruptions. No two other regions in the world are as deeply integrated as the United States and Europe, according to the 2024 Transatlantic Economy Report from the U.S. Chamber of Commerce, AmCham EU, Johns Hopkins SAIS and the Transatlantic Leadership Network. The report states: "the $8.7 trillion transatlantic economy employs more than 16 million workers in mutually onshored jobs on both sides of the Atlantic. It is the largest and wealthiest market in the world, accounting for half of total global personal consumption and close to one-third of world GDP in purchasing power. Ties are solid in foreign direct investment, portfolio investment, banking claims, trade and affiliate sales in goods and services, digital links, energy, mutual R&D investment, patent cooperation, technology flows, and sales of knowledge-intensive services." The services agreement will be overseen by a committee chaired by Pia De Lima and Daniel Diaz, NOVUS INK Advisors' Managing Partners, and Andreas Dal Santo, Solidus Capital Group's Managing Director. NOVUS INK Advisors is based in Miami. Solidus Capital Group, affiliated with Atlantic Business Labs, is based in New York. NOVUS INK Advisors is a communication, public and government affairs lobbying firm. NOVUS INK Advisors' practice areas include Corporate, Band and Product Reputation, Business Strategy, Crisis and Reputation Risk, Financial Services, Investor Relations, Mergers & Acquisitions, Brand and Product Marketing Communications Strategy, and Public and Government Affairs. NOVUS INK Advisors is a registered lobbying firm. To learn more, visit: www.NovusInk.com. Solidus Capital Group specializes in management consulting, business valuation, and board advisory services for firms expanding into North America, Latin America, and Europe. It is spearheading an ecosystem of companies, consultants, and subject matter experts with experience from different industries and regions to support corporate and institutional clients' global strategies and growth into new markets. To learn more, visit www.solidus-capital.com. CONTACTS: NOVUS INK Advisors: client.services@NovusInk.com Solidus Capital Group: client.services@Solidus-Capital.com Contact Details NOVUS INK Advisors Client Services client.services@NovusInk.com Company Website https://www.novusink.com/about

June 11, 2024 09:30 AM Eastern Daylight Time

Room to Roam: ‎The Elephant’s Path to Climate Resilience

News Media Group, Inc.

Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

June 10, 2024 07:00 AM Eastern Daylight Time

Video

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a medical device company dedicated to transforming the diagnosis and treatment of diseases or disorders related to the nervous system. At the core of Autonomix's innovative approach is a first-in-class technology platform featuring a catheter-based microchip sensing array. This technology boasts an unprecedented ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies. This breakthrough has paved the way for transvascular diagnosis and treatment of nervous system diseases virtually anywhere in the body, offering a new horizon of medical possibilities and market opportunities. Clinical Studies In Pancreatic Cancer Pain Autonomix has initiated its first clinical study targeting pancreatic cancer pain, marking a significant milestone in its ongoing medical innovation. Pancreatic cancer represents a considerable unmet medical need, particularly concerning pain management. Effective solutions in this area are critically needed, as current relief options for pancreatic diseases are limited to drugs like opioids. In light of that, the initiation of these clinical studies represents a crucial step toward addressing this substantial healthcare challenge for suffering patients. Market Opportunities In addition to addressing the pain relief needs of patients, Autonomix’s technology presents significant market opportunities across various medical fields. By accurately targeting the nervous system, Autonomix aims to address unmet needs and improve treatments for a wide range of conditions including but not limited to: Pancreatic Cancer Pain: The successful application of Autonomix's technology in pancreatic cancer pain management would not only help pancreatic cancer patients find relief from pain but also unlocks significant market potential. Pancreatic cancer pain management is part of a $2.2 billion market for pancreatic cancer treatment. Chronic Pain: This market presents a significant opportunity estimated at $75 billion. Conditions such as lower back pain, pelvic pain, urinary tract pain, digestive disorders and other tumor-related pain are prevalent and often inadequately managed with current therapies, particularly opioids. Autonomix's technology offers the potential to significantly reduce or eliminate the dependence on opioids, providing a safer and more effective solution for chronic pain management. Cardiovascular Diseases: With a market opportunity estimated at $23 billion, Autonomix's technology could revolutionize the treatment of conditions like hypertension and cardiovascular disease. By targeting the nervous system's role in these diseases, more precise and effective treatments could be developed. Pulmonary Diseases: Chronic obstructive pulmonary disease (COPD) is another area where Autonomix's technology could have a substantial impact. The market for COPD treatments is estimated to be around $18 billion with considerable growth ahead, driven by the need for more effective and less side-effect-prone therapies. Autonomix's approach could provide a new paradigm in managing this debilitating condition. Meeting Unmet Needs with Innovative Solutions Current drug therapies for many of these conditions often come with significant side effects and do not adequately address the underlying issues. Autonomix's technology offers a promising alternative by providing targeted, nerve-based treatments that could improve patient outcomes and quality of life. This innovative approach aligns with Autonomix's mission to dramatically enhance the lives of millions by enabling precise and effective nerve-targeted treatments. In doing so, Autonomix can both detect and ablate malfunctioning nerves in one simple procedure, effectively opening new treatment options in the field of electrophysiology. The Full Opportunity Autonomix Medical sits at the forefront of a potential revolution in medical treatment for diseases driven by the nervous system. The company’s advanced technology platform not only offers hope for better management of pancreatic cancer pain, but also opens the door to addressing numerous other conditions with significant unmet need. By providing physicians with powerful new tools for diagnosis and treatment, Autonomix is poised to make a profound impact on the future of healthcare. Featured photo by Irwan on Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

June 06, 2024 09:00 AM Eastern Daylight Time

Image

Healthcare

Expert Tips to Support and Celebrate Aging Pets

Shedding Light on Cystic Fibrosis

Roberts & Ryan Inc. expands its internship program in partnership with the Boys and Girls Club of Harlem.

Stupid Cancer Announces CancerCon Live 2024 in Austin, Texas

Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer

Busting the Myths Around Weight Loss Medication

NOVUS INK Advisors and Solidus Capital Group Team-up to Serve Growing Transatlantic Commercial Interests of Mid-Market Enterprises

Room to Roam: ‎The Elephant’s Path to Climate Resilience

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management